Veru (VERU) Cash from Operations (2010 - 2026)
Veru (VERU) posted quarterly Cash from Operations of 8884415.0 for Q1 2026, down 14.35% year-over-year from 10373006.79 in Q1 2025, and down 43.3% quarter-over-quarter from 6200000.0 in Q4 2025.
Veru (VERU) Cash from Operations (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Cash from Operations for 17 consecutive years, with 8884415.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 14.35% year-over-year to 8884415.0; the TTM figure through Mar 2026 stood at 26014965.0 (up 10.6% YoY), while the FY2025 annual figure was 30000000.0, down 38.25% from the prior year.
- Cash from Operations retreated to 8884415.0 in Q1 2026 per VERU's latest filing, from 6200000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 3946677.0 in Q1 2022 and bottomed at 34534028.0 in Q4 2022.
- Historically, Cash from Operations has averaged 11390908.29 across 5 years, with a median of 7769450.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 2488.88% — and 2023, when it jumped 82.57%.
- Veru's Cash from Operations stood at 34534028.0 in 2022, then surged by 82.57% to 6020389.0 in 2023, then sank by 87.7% to 11300000.0 in 2024, then soared by 45.13% to 6200000.0 in 2025, then plunged by 43.3% to 8884415.0 in 2026.
- Business Quant data shows VERU's Cash from Operations at 8884415.0 in Q1 2026, 6200000.0 in Q4 2025, and 5448248.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | -5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.50 Mn |
| Jun 30, 2026 | -5.50 Mn |
| Mar 31, 2026 | -8.88 Mn |
| Mar 31, 2026 | -8.88 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -5.45 Mn |
| Sep 30, 2025 | -5.45 Mn |
| Jun 30, 2025 | -5.48 Mn |
| Jun 30, 2025 | -5.48 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | -11.30 Mn |
| Dec 31, 2024 | -11.30 Mn |
| Sep 30, 2024 | -4.38 Mn |
| Sep 30, 2024 | -4.38 Mn |
| Jun 30, 2024 | -5.65 Mn |
| Jun 30, 2024 | -5.65 Mn |
| Mar 31, 2024 | -5.65 Mn |
| Mar 31, 2024 | -5.65 Mn |